Cancer is a leading
cause of death worldwide and its incidence
is unfortunately anticipated to rise in the next years. On the other
hand, vascular endothelial growth factor receptor 2 (VEGFR-2) is highly
expressed in tumor-associated endothelial cells, where it affects
tumor-promoting angiogenesis. Therefore, VEGFR-2 is considered one
of the most promising therapeutic targets for cancer treatment. Furthermore,
some FDA-approved benzimidazole anthelmintics have already shown potential
anticancer activities. Therefore, repurposing them against VEGFR-2
can provide a rapid and effective alternative that can be implicated
safely for cancer treatment. Hence, 13 benzimidazole anthelmintic
drugs were subjected to molecular docking against the VEGFR-2 receptor.
Among the tested compounds, fenbendazole (FBZ,
1
), mebendazole
(MBZ,
2
), and albendazole (ABZ,
3
) were
proposed as potential VEGFR-2 antagonists. Furthermore, molecular
dynamics simulations were carried out at 200 ns, giving more information
on their thermodynamic and dynamic properties. Besides, the anticancer
activity of the aforementioned drugs was tested in vitro against three
different cancer cell lines, including liver cancer (HUH7), lung cancer
(A549), and breast cancer (MCF7) cell lines. The results depicted
potential cytotoxic activity especially against both HUH7 and A549
cell lines. Furthermore, to improve the aqueous solubility of MBZ,
it was formulated in the form of mixed micelles (MMs) which showed
an enhanced drug release with better promising cytotoxicity results
compared to the crude MBZ. Finally, an in vitro quantification for
VEGFR-2 concentration in treated HUH7 cells has been conducted based
on the enzyme-linked immunosorbent assay. The results disclosed that
FBZ, MBZ, and ABZ significantly (
p
< 0.001) reduced
the concentration of VEGFR-2, while the lowest inhibition was achieved
in MBZ-loaded MMs, which was even much better than the reference drug
sorafenib. Collectively, the investigated benzimidazole anthelmintics
could be encountered as lead compounds for further structural modifications
and thus better anticancer activity, and that was accomplished through
studying their structure–activity relationships.